HIV Treatment Options For Patients Improve In Japan
This article was originally published in PharmAsia News
Executive Summary
Japan Tobacco brings Stribild home after U.S./EU launches by Gilead. Johnson & Johnson reduces patient burden with higher dose Prezista.
You may also be interested in...
The New Quad: FDA Approves Gilead’s 4-In-1 HIV Pill Stribild
With cost concerns already arising, the sponsor says it is working to ensure the drug is covered by state AIDS Drug Assistance Programs.
Ranbaxy’s GMP Woes Puts Spotlight On Daiichi Sankyo Due Diligence
Whether Daiichi Sankyo will be able to claim damages from Ranbaxy’s former owners will depend on what Daiichi Sankyo knew before the acquisition, and its chances of proving misrepresentation may be slim.
Are Novartis’ Advertising Charges In Japan The Tip Of The Iceberg?
Prosecutors are looking into allegations of exaggerated advertising, but a bribery investigation may be the real aim for authorities.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports